New hope for rare kidney cancer: drug trial targets tough tumors
NCT ID NCT07438626
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called sacituzumab tirumotecan in 20 people with a rare and aggressive kidney cancer (SMARCB1-deficient renal medullary carcinoma) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink or control the cancer. Researchers will also monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.